Ciprofloxacin Lawsuit

A Brief Guide to Filing a Ciprofloxacin Lawsuit

Ciprofloxacin: Description and Side Effects

Ciprofloxacin, which is sold under the brand names Cipro and Proquin, is used to treat certain bacterial infections. In addition to treating these ailments, Ciprofloxacin is administered to patients who suffer from infections caused by airborne anthrax. Also, Ciprofloxacin—in the extended-release variety, is used to treat certain urinary trait infections. Ciprofloxacin belongs to a class of medications known as fluoroquinolones; the antibiotic is effective by killing bacteria that causes the aforementioned infections.

Side Effects of Ciprofloxacin include:

•Nausea; stomach pain; vomiting; heartburn; diarrhea; urgent need to urinate; headache; vaginal discharge or itching and hives

Severe side effects of Ciprofloxacin include:

•The development of blisters or rash; difficulty breathing or swallowing; wheezing; hoarseness; tingling of the neck, face, throat, eyes, lips, hands, feet, lower legs or ankles; wheezing; rapid or irregular heartbeat; extreme fatigue; unusual bleeding or bruising; fever; loss of appetite; flu-like symptoms; seizures; confusion; difficulty falling or staying asleep; paranoia; depression and hallucinations

Ciprofloxacin Litigation History:

To date, there has not been a successful class action litigation suit regarding adverse effects of the antibiotic Ciprofloxacin. A class action Ciprofloxacin lawsuit was advanced in 2001 on behalf of many government and post office employees who were issued the drug after being potentially exposed to anthrax. This litigation over Ciprofloxacin side effects was dismissed in 2004.

That same year, the FDA required that prescription information be updated to include warnings about nerve damage, colon swelling and similar severe responses to the medication. Many of these complaints advanced as part of the 2001 Ciprofloxacin lawsuit on behalf of those administered the drug to control the effects of anthrax exposure. In the wake of the FDA's warning, however, successful litigation with this revelation of Ciprofloxacin side effects was not advanced.

When researching what is Ciprofloxacin litigation likely to consist of, patients should keep the previous lack of legal success in mind. Though a number of significant Ciprofloxacin side effects have been reported, these have only led to the institution of FDA warnings.
Tendon rupture is the prominent side effect that has yielded the bulk of Ciprofloxacin litigation. By 2008, the FDA had received Ciprofloxacin side effects reports that included 262 such cases This information; however; has not yet spurred any successful Ciprofloxacin lawsuit.

Users wanting to file a Ciprofloxacin lawsuit should be aware of a new warning issued by the FDA in 2011 concerning people with "myasthenia gravis". This updated information stated that what adverse reactions included the exacerbation of existing myasthenia gravis. A Ciprofloxacin lawsuit may be filed by patients who do not receive sufficient warning before taking the drug.

Ciprofloxacin FDA Recalls:

Despite reports regarding Ciprofloxacin's risk to patients, the drug has not been subject to recalls. At this time, the FDA is not actively conducting further research into Ciprofloxacin side effects. Pending the successful advancement of a Ciprofloxacin lawsuit, it is difficult to predict that future litigation is likely to meet with greater success.

If you wish to litigate over what are Ciprofloxacin’s serious adverse effects, prepare all physician records of your treatment for an attorney to review. A lawyer experienced in pharmaceutical law can evaluate the likelihood of a Ciprofloxacin lawsuit being the first to succeed in civil court.

Sources:

1. United States National Library of Medicine “Ciprofloxacin” retrieved from:

www.ncbi.nlm.nih.gov/pubmedhealth/PMH0000878/

2. Ciprofloxacin-Hydrochloride". The American Society of Health-System Pharmacists.

3. http://www.fda.gov/downloads/Drugs/EmergencyPreparedness/

BioterrorismandDrugPreparedness/UCM130802.pdf

4. Cipro Labeling Revision 04/06/2009 Supplement 073".

U.S. Food and Drug Administration (FDA). 6 April 2009.

5. http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm126085.htm